Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema.

Saved in:
Bibliographic Details
Title: Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema.
Authors: Banerji A; Massachusetts General Hospital, Boston, Mass. Electronic address: abanerji@mgh.harvard.edu., Craig T; Department of Allergy, Asthma and Immunology, Penn State University, Hershey, Pa; VinMec/VinUniversity Institute of Immunology, Hanoi, Vietnam., Sitz K; Acuro Research Inc, Little Rock, Ark., Li HH; Institute for Asthma & Allergy, Chevy Chase, Md., Lumry W; Allergy and Asthma Research Associates, Dallas, Tex., Adatia A; University of Alberta, Edmonton, Alberta, Canada., Yang W; Ottawa Allergy Research Corporation, Ottawa, Ontario, Canada., Jacobs JS; Allergy and Asthma Clinical Research, Walnut Creek, Calif., Tachdjian R; University of California-Los Angeles, Los Angeles, Calif., Soong W; AllerVie Health and Clinical Research, Birmingham, Ala., Manning M; Medical Research of Arizona, Scottsdale, Ariz., Wedner J; Washington University Physicians, St Louis, Mo., Savic S; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom., Manson A; Addenbrooke's Hospital, Cambridge, United Kingdom., Valerieva A; Medical University of Sofia, Sofia, Bulgaria., Gunsior M; Astria Therapeutics, Boston, Mass., Mugundu G; Astria Therapeutics, Boston, Mass., Cohen T; Astria Therapeutics, Boston, Mass., Bernard K; Astria Therapeutics, Boston, Mass., VanEenwyk C; Astria Therapeutics, Boston, Mass., Joseph K; Astria Therapeutics, Boston, Mass., Best JM; Astria Therapeutics, Boston, Mass., Morabito C; Astria Therapeutics, Boston, Mass., Riedl MA; University of California-San Diego, La Jolla, Calif.
Source: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2026 May; Vol. 157 (5), pp. 1127-1135.e6. Date of Electronic Publication: 2026 Mar 05.
Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Mosby Country of Publication: United States NLM ID: 1275002 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6825 (Electronic) Linking ISSN: 00916749 NLM ISO Abbreviation: J Allergy Clin Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-6825
DOI:10.1016/j.jaci.2026.02.034